Do you want to get instant company alerts to the front screen of your smartphone?
Download the Vox Markets app here: www.VoxMarkets.co.uk/app
On today’s Vox Markets Podcast: Reabold Resources, Predator Oil & Gas, Shield Therapeutics and Russ Mould on Macro and 3 Stocks
Stephen Williams, Co-Chief Executive Officer of Reabold Resources (RBD) talks about drilling operations which have started at the West Newton appraisal well, onshore UK.
Reabold Resources plc is an investing company investing in the exploration and production (“E&P”) sector. The Company’s investing policy is to acquire direct and indirect interests in exploration and producing projects and assets in the natural resources sector, and consideration is currently given to investment opportunities anywhere in the world.
As an investor in upstream oil & gas projects, Reabold aims to create value from each project by investing in undervalued, low-risk, near-term upstream oil & gas projects and by identifying a clear exit plan prior to investment.
Paul Griffiths, Chief Executive Officer of Predator Oil & Gas (PRD) discusses the significance of the prospective resource update on their onshore Morocco permits.
Predator is an oil and gas exploration company with the objective of participating with FRAM Exploration Trinidad Ltd. in further developing the remaining oil reserves in the producing Inniss Trinity oil field onshore Trinidad, primarily through the application of C02 EOR technology.
In addition, Predator also owns and operates exploration and appraisal assets in current licensing options offshore Ireland, for which Successor Authorisations have been applied for, adjoining Shell’s Corrib gas field in the Slyne Basin on the Atlantic Margin and east of the Kinsale gas field and Barryroe oil field in the Celtic Sea.
Predator is operator of the Guercif Petroleum Agreement onshore Morocco which is initially prospective for Tertiary gas in prospects less than 10 kilometres from the Maghreb gas pipeline.
(Interview starts at 11 minutes 40 seconds)
Dr Jackie Mitchell, VP of Regulatory Affairs and Quality at Shield Therapeutics (STX) talks about the granting of a major extension in Switzerland for their lead product Feraccru®.
Shield is a de-risked, commercial stage, pharmaceutical company delivering innovative specialty pharmaceuticals to address patients’ unmet medical needs. The Company’s clear purpose is to help its patients become people again, by enabling them to enjoy the things that make the difference in their everyday lives. The Group has a marketed product, Feraccru®, for the treatment of iron deficiency in adults which has exclusive IP rights until the mid-2030s. Feraccru® is commercialised in the European Union by Norgine BV and the US Food and Drug Administration (FDA) is currently considering a New Drug Application (NDA), with a PDUFA (Prescription Drug User Fee Act) date of 27th July 2019.
(Interview starts at 24 minutes 17 seconds)
Russ Mould, Investment Director at stockbroker AJ Bell talks about:
The positive U.S. earnings season but how the outlook isn’t as rosy and the following stocks:
(Interview starts at 31 minutes 8 seconds)